Clover Health Investments (CLOV) Cash & Equivalents (2019 - 2026)

Clover Health Investments' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $173.3 million for Q1 2026.

• Quarterly Cash & Equivalents rose 11.47% year-over-year to $173.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.3 million (up 11.47% YoY) and the FY2025 annual result came in at $78.3 million, down 59.75% from the prior year.
• Cash & Equivalents was $173.3 million for Q1 2026 at Clover Health Investments, up from $78.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $382.9 million in Q3 2022 and bottomed at $78.3 million in Q4 2025.
• A 5-year average of $219.9 million and a median of $194.5 million in 2024 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 89.29% in 2022, while the deepest fall reached 65.4% in 2022.
• Clover Health Investments' Cash & Equivalents stood at $103.8 million in 2022, then rose by 18.38% to $122.9 million in 2023, then surged by 58.34% to $194.5 million in 2024, then plunged by 59.75% to $78.3 million in 2025, then soared by 121.28% to $173.3 million in 2026.
• Business Quant data shows CLOV's Cash & Equivalents at $173.3 million in Q1 2026, $78.3 million in Q4 2025, and $190.1 million in Q3 2025.